Welcome to the 10th CAR-TCR Summit!
Hope is renewed for the cell therapy industry in 2025 fuelled by a 30% year on year increase in investment, notably in the cases of Arsenal Bio, Enara Bio and AvenCell. Landmark approvals for solid tumors from Adaptimmune and Iovance, along with significant clinical progress from Adicet Bio and Cartesian Therapeutics all signify huge strides forward for the industry. Don’t sit back and watch. Join the 10th Anniversary of the CAR-TCR Summit to reflect on a decade of progress whilst engaging in solutions-driven discussions that will empower you to tackle cell therapy development challenges to help shape the future of the field.
Built in collaboration with industry veterans including AstraZeneca, Cabaletta Bio, Arsenal Bio, Bristol Myers Squibb, Kyverna Therapeutics, T-knife Therapeutics, and Umoja Biopharma, this meeting will equip you to overcome challenges across the entire development landscape - spanning durability, manufacturing timelines, potency assay matrix, solid tumor targeting, biomarker data, high cost of goods, scale up and scale out, and more, to make rapid advancements in the clinic and beyond.
Whether your focus is on Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, or Analytical Development you can expect to gain in-depth insights across the entire cell therapy value chain.
Your Complete Guide to the Meeting is Here:
Key Highlights of the 10th CAR-TCR Summit:
Holistic Coverage of Multiple Cell Types
51% CAR-Ts, 20% TCRs, 18% NK, Gamma Delta, Macrophages, TILs and Tregs, and 11% multiple cell types to give full visibility of advancements in cell therapy
Comprehensive Coverage of Indications
Spanning haem, and solid tumors, to autoimmune indications - understand the challenges when targeting different indications from cell engineering to patient recruitment nuances
Brand New Biotech & Pharma Partnering Day
Join some of the key players involved in recent mergers and acquisitions, including AstraZeneca, Johnson & Johnson, and Merck, to gain insider insights into the decision-making processes
New Clinical Data
from Capstan Therapeutics on in vivo CAR-T, Legend Biotech on solid tumors targeting, and MiNK Therapeutics on the success of cell therapy beyond oncology
Full Cell Therapy Landscape Coverage
Gain competitive insight across multiple scopes of indications from oncology to autoimmune to cover the growing trial expansion and ensure you stay ahead of the curve
Attending Companies:
Expert Speakers Include:
Christopher Tan
Executive Director - S&E, Business Development ,Licensing, Infectious Diseases, Vaccines & Oncology
Merck
Network with Experts from the Entire Cell Therapy Ecosystem
“I’m excited to join this year’s summit to exchange bold ideas, share first-in-human data on iNKT cell therapy, and explore how we can expand the reach of cell therapy to patients suffering from autoimmune diseases. It’s a critical moment for collaboration and scientific innovation as we move beyond oncology.”
MiNK Therapeutics, 2025 Speaker
Lead Partner
Expertise Partners
